The effect of thiazolidinediones on adiponectin serum level: A meta-analysis

Diabetes, Obesity and Metabolism

Volumn 10, Issue 5, 2008, Pages 367-375

  Riera Guardia, N ^a   Rothenbacher, D ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; FENOFIBRATE; GLIBENCLAMIDE; GLIMEPIRIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; META ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PUBLICATION; REVIEW; SYSTEMATIC REVIEW;

EID: 42149134825     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00755.x     Document Type: Review

References (44)

1. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: A model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280: E827-E847.
2. Nawrocki AR, Scherer PE. Keynote review: The adipocyte as drug discovery target. Drug Discov Today 2005; 10: 1219-1230.
3. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
4. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
5. Hotta K, Funahashi T, Arita Y et al. Plasma concentration of a novel adipose specific protein adiponectin in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
6. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: More than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450.
7. John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther 2006; 23: 1511-1523.
8. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005; 22 (Suppl. 2): 3-10.
9. Spiegelman BM. PPARγ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
10. Maeda N, Takahashi M, Funahashi T et al. PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
12. Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in "meta-epidemiological"research. Stat Med 2002; 21: 1513-1524.
13. Sterne JA, Egger M, Smith G. Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105.
14. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1045-1055.
15. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
16. Begg CB, Mazumdar M. Operating characteristics of rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
17. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 119-129.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
19. Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 182-188.
20. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with piogliatzone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568-576.
21. Buras J, Reenstra WR, Orlow D, Horton ES, Veves A. Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes. Obes Res 2005; 13: 1167-1174.
22. Osei K, Gaillard T, Kaplow J, Bullock M, Schuster D. Effects of rosiglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 2004; 53: 1552-1557.
23. Pfützner A, Marx N, Lübben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control. J Am Coll Cardiol 2005; 45: 1925-1931.
24. Phillips SA, Ciaraldi TP, Kong AP et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52: 667-674.
25. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006; 290: E42-E46.
26. Yilmaz MI, Sonmez A, Caglar K et al. Peroxisome proliferators-activated receptor γ (PPAR-γ) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. Endocrine 2004; 25: 207-214.
27. Jung HS, Youn BS, Cho YM et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 2005; 54: 314-320.
28. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term piogliatzone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005; 46: 773-778.
29. Pfützner A, Schöndorf T, Seidel D et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: Results form a double-blind oral combination study with glimepiride. Metabolism 2006; 55: 20-25.
30. Wagner JA, Larson PJ, Weiss S et al. Individual and combined effects of peroxisome proliferator-activated receptor α and γ agonists, fenofibrate and rosiglitazone on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J Clin Pharmacol 2005; 45: 504-513.
31. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 4312-4319.
32. Samaha FF, Szapary PO, Iqbal N et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 624-630.
33. Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499.
34. Adachi T, Inoue M, Hara H, Maehata E, Suzuki S. Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients. J Endocrinol 2004; 181: 413-417.
35. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosigliatzone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176.
36. Nishio K, Sakurai M, Kusuyama T et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006; 29: 101-106.
37. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
38. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
39. Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005; 26: 1640-1646.
40. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-539.
41. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
42. Von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 2006; 52: 853-859.
43. Teoh H, Strauss MH, Szmitko PE, Verma S. Adiponectin and myocardial infarction: A paradox or a paradigm? Eur Heart J 2006; 27: 2266-2268.
44. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.